In this pilot study, the predictive value of Octreotide scintigraphy (Octreoscan) and/or Chromogranin-A (CgA) was investigated in patients with hormone-refractory prostate cancer treated with Octreotide acetate. In total, 20 patients with progressive disease and bone metastases entered the trial. At baseline Octreoscan, CgA, PSA, alkaline phosphates (ALP) and two self-administered questionnaires (EORTC QLQ C-30 (v3) and brief pain index) were performed and a diary of the pharmaceutical was started. The treatment consisted of Octreotide (Sandostatin LAR) acetate 30 mg intramuscular injection every month. The blood samples and questionnaires were repeated every month until 3 months. Clinical responder was defined as a patient with increased global health score more than 10 units and stable or decreased pain score without an increase in analgesic. In all, 17 patients were treated per protocol, and four were assessed as clinical responders. Six patients developed a reduction in ALP (median À26%, range À5 to À78%). All patients increased in PSA. At baseline, three patients had a negative Octreoscan and the patients with positive lesions, demonstrated uptake of low intensity. At baseline the CgA was elevated above the normal range in 15 of the patients, and during treatment five patients decreased their CgA to the normal range. Neither baseline Octreoscan nor CgA could identify the clinical reponders. A minority of patients improves their health-related quality of life. The decrease and normalization of CgA levels in five patients during therapy indicates therapeutic activity but Octreoscan and CgA could not identify clinical responders.
Introduction
The hormone-refractory state of metastatic prostate cancer presents a therapeutic challenge. Although there are signs that indicate a reduced mortality in prostate cancer, 1 the disease is still the most common cause of death among the various cancer forms in Sweden. 2 When hormonal treatment becomes ineffective the patient's condition becomes dominated with painful bone metastases, anemia, fatigue and weight-loss. Recently, the use of docetaxel has demonstrated increased survival, although the effect is moderate. 3, 4 The need for new therapeutic alternatives is obvious. One source of interest is the neuroendocrine differentiation of prostate cancer cells within the prostate and metastases. 5 Small pilot studies have addressed the question of the efficacy of somatostatin analog treatments with conflicting results. [6] [7] [8] [9] [10] [11] [12] One can hypothesize that the presence and/or amount of somatostatin receptor positive cells in metastases would reflect the sensitivity to treatment, in analogs with the findings regarding neuroendocrine tumors as carcinoids. 13 This study will address the question of whether 111In-labeled Octreotide or CgA levels can predict a positive therapeutic response to Octreotide acetate in a slow-release formula (Sandostatin LAR s ).
Materials and methods

Patients
Between January 2002 and June 2002, 20 patients were included in this prospective two-center (Karlskrona; n ¼ 16 and Lund; n ¼ 4) study. The inclusion criteria were progressive hormone-refractory prostate cancer with bone metastases. Hormone-refractory was defined as prostate-specific antigen (PSA) -levels X5 ng/ml and an increase 4100% of the lowest value, combined with clinical symptoms as increased pain or new metastases at bone scintigraphy. The patients had received androgen deprivation in form of either orchiectomy or luteinizing hormone-releasing hormone (LH-RH) analogs. Antiandrogen treatment was required to be finished at least 6 weeks before entrance of the study, to avoid withdrawal symptoms. Androgen deprivation therapy was continued during the trial. The characteristics of patients at baseline are demonstrated in Table 1 .
Questionnaires and daily notebook
The patients answered a self-assessed health-related questionnaire at baseline and at follow-up. The European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 (v3), a quality of life instrument, was used.
14 The function scores including global health score and symptom scores were calculated according to EORTC criteria. High function scores were equivalent to a high to good function. High scores on the symptom scale indicated frequent and disturbing symptoms. A clinically significant difference was defined as changes of more than 10 units according Osoba et al. 15 A 10 item questionnaire based on the brief pain inventory (BPI) was answered at baseline and follow up. The BPI asks patients to rate their current pain intensity and also pain in the last 24 h at its worst, leas and average by using a numeric scale of 0-10. Each rating scale is bounded by the words 'no pain' at the 0 end and 'pain as bad as you can imagine' at the other. Using similar scales of 0-10, patients are also asked to rate the extent to which their pain interferes with seven quality of life domains that include general activity, walking, mood, sleep, work, relations with other persons and enjoyment of life. These scales are bounded by the words 'does not interfere' and 'interferes completely'. 16 The patients also reported their daily consumption of analgesics, in terms type of pharmaceuticals, dosage and any extra need for analgesic in a diary. To facilitate data interpretation, all the opioids were converted to milligrams equivalent of oral morphine. Also, the use of corticosteroids and nonsteroidal antiinflammatory drugs (NSAID) was noted. A clinical responder was defined as a patient with global health score increased more than 10 units at end of trial, with decreased or unchanged pain not explained by increased in analgesics or addition of corticosteroid/NSAID.
Bone scintigraphy
Bone scintigraphy was performed at inclusion. A wholebody scan was performed 3-4 h after the intravenous (i.v.) administration of 600 MBq of 99m Tc methylene diphosphonate. Areas of abnormal radionuclide uptake with a typical pattern of malignancy were classified as bone metastasis and if equivocal a complementary X-ray or CT-investigation was performed to rule out benign disease. Each bone scintigraphy was graded according to the classification of Soloway, where 0 represents normal or abnormal due to benign disease, 1 represents less than 6 metastases, of which each is less than 50% the size of a vertebral body, 2 represents between 6 and 20, size of lesion as described, 3 represents more than 20, but less than a super scan and 4 represents super scan or its equivalent (more than 75% of the ribs, vertebrae and pelvic bones). 17 
Octreotide scintigraphy
At inclusion and immediately after the treatment period scintigraphy was performed after i.v. administration of 111In-pentetreotide, a [111In-DTPA-D-Phe-] conjugate of octreotide, a somatostatin analog, which binds to somatostatin receptor of primarily subtypes 2 and 5 (OctreoScan; Mallinckrodt Medical, Petten, the Netherlands). Whole-body images were performed in all patients 4 h and 24 h after injection i.v. of 200-220 MBq of 111In-pentetreotide. A dual head gamma camera (Multispect2, Siemens Medical Systems, Hoffman Estates, USA) was used. Anterior and posterior images were obtained with a medium energy collimator and acquired into a 1024 Â 256-word matrix with a speed of 10 and 15 cm/min at 4 and 24 h, respectively. Additionally, in all but three patients, SPECT-images of areas with equivocally abnormal uptake were obtained using a triple head gamma camera equipped with medium energy collimators (MultiSpect3, Siemens Medical Systems, Hoffman Estates, USA). Projection over 3601 (30 s per stop) were acquired in a 128 Â 128 matrix. Abnormal uptakes on Octreotide scintigraphy were compared with metastases on bone scintigraphy and the intensity of tumor radioactivity uptake was scored according to the scale suggested by Krenning et al. 18 The scoring grades used were 4 ¼ intense, 3 ¼ clear (higher than liver uptake), 2 ¼ clear but faint (lower than or equal to liver uptake), 1 ¼ equivocal and 0 ¼ no accumulation.
Chromogranin A (CgA)
The CgA concentrations were measured by competitive radioimmunoassay, using polyclonal antibodies raised in Predicting octreotide therapy KM Kalkner et al rabbits. 19 These antibodies bind to both intact and partly degraded CgA. This assay has a high precision with intra-and interassay coefficients of variation of less than 6.4%. The upper reference limit for normal range was 4 nmol/l. 19 Octreotide acetate treatment Initially, the patients received 100 mg Octreotide acetate (Sandostatin s , Novartis) subcutaneously three times a day for three days in order to identify patients who would react negatively to octreotide. After this initial test, the patients received 30 mg of long-acting octreotide acetate (Sandostatin LAR s , Novartis) intramuscularly (i.m.) into the gluteal muscle at 4-weekly intervals. After 3 months, the study was completed and prolonging the treatment was optional. Additionally, it was optional to treat the patients with pancreatin orally to reduce gastrointestinal tract side effects.
Follow-up
The patients received a monthly physical examination and measurement of serum PSA, alkaline phosphates (ALP) and CgA levels. EORTC QLQ C-30 was answered every second week and BPI was answered every week. The daily consumption of analgesics was reported in a diary. After 3 months the study was finished, and it was optional to continue with Sandostatin LAR.
Statistics
Survival curves were estimated using the Kaplan-Meier method. Wilcoxon's two sample tests were used in order to compare two groups of patients, that is, clinical responders versus not clinical responders. For comparison of more than two groups, Kruskal-Wallis was used. Nonparametric analyses were chosen since the data were not normally distributed and since ordinal data were used in questionnaires. Differences in count and frequency data were analyzed using the Fisher's exact test. Correlation was calculated according to Spearman's rank correlation. The tests were performed with SASt. P-values equal to or less than 0.05 were considered statistically significant.
Results
In total, 20 patients were treated and analyzed with intention to treat. Three patients did not complete the whole follow-up giving 17 patients analyzed per protocol. The results of intention to treat analysis is reported but no significant differences were observed between the results from intention to treat and analysis per protocol. During the 3 months of treatment, four out of the 20 patients increased their global health score according to EORTC QLQ C-30 more than 10 units, which was defined as clinically significant improvement. The four patients are referred to as clinical responders. Half of the patients (10/20) experienced an impairment (410 units) and the remaining six patients assessed their global health as unchanged. These patients are referred to as nonresponders and unchanged, respectively. The increase in global health score could not be explained by higher morphine dosage or additional NSAID or corticosteroids. No therapy-related side effects were observed.
All patients had an increase in PSA from baseline to end of the study. The average PSA level at baseline was 243 mg/l (9-1128 mg/l) and at end of the study 542 mg/l (22-2313 mg/l). PSA at baseline did not predict clinical responders. No statistical difference was observed between PSA increase in clinical responders and nonresponders. However, the nonresponders more than doubled their PSA, whereas the responders did not (Figure 1) .
CgA
Six patients experienced a decrease in their ALP levels during therapy; however, there was no correlation to clinical responders. No differences in Hb-levels and body weight were noticed at follow-up Table 3 .
In total, 18 of 20 patients had performed an octreotide scintigraphy at baseline. Three patients did not have any abnormal uptake and 15 patients had at least one abnormal uptake in the skeleton. Generally, abnormal uptakes were characterized by low intensity. Seventeen uptakes were assessed as grade 1, and 30 were assessed as grade 2, given in total 47 abnormal skeletal uptakes. The presence of uptake, the intensity or the number of uptakes could not predict clinical responders, nonresponders and stable disease. In Table 2 the Soloway score and number of uptake at octreotide scintipraphy and the result of octreotide acetat treatment is listed for the patients (Tables 2 and 3) . 
Predicting octreotide therapy KM Kalkner et al
In order to check the validity of answers between pain assessment in BPI and in EORTC QLQ C-30 a Spearman rank correlation was performed demonstrating significant correlation (Po0,01).
The overall survival according to clinical responders, nonresponders and stable disease is demonstrated in Figure 2 .
Six patients were considered to have a possible positive effect of Sandostatin-LAR based on response in clinical and/or laboratory variables such as PSA or ALP, and treatment was continued off label for a median time of 5 months (range 3-9 months) until disease progression were observed in five patients. In one long-term clinical responder, treatment with octreotide acetate off label has been given together with LH-RH-agonist, without any other interfering medication, for over 3 years: PSA was 158 and ALP 4. 
Discussion
Preclinical considerations
In the search for new therapeutic alternatives for patients with hormone-refractory prostate cancer, somatostatin analogs have been advocated. Somatostatin is known to inhibit cell secretion and prevent cell proliferation by inducing cell cycle arrest and/or apoptosis (reviewed by Patel 20 ). Prostate tumor cells express somatostatinbinding sites, and somatostatin analogs have been reported in vitro to reduce tumor growth and/or function as cytotoxic agents in several investigations. [21] [22] [23] These antineoplastic effects are mediated by means of a family of five G-protein-coupled somatostatin receptors (SSTR1-5), which bind the naturally occurring peptides somatostatin-14 (SST-14) and somatostatin-28 (SST-28) with similar affinity. Somatostatin receptors can mediate direct antineoplastic effects when expressed on tumor cells, and indirectly when expressed by nontumor cells by inhibiting the secretion of hormones and growth factors involved in promoting tumor cell growth and modulating angiogenesis and immune cell function. 20 Reubi and collaborators showed that primary prostatic cancer cells preferentially bind SST-28 rather than the synthetic peptide octreotide, which only binds to SSTR subtype 2 with high affinity, and to SSTR subtypes 5 and 3 with moderate affinity. 24 However, prostatic metastatic lesions have been reported to bind octreotide 9, and it has been concluded that it is the tumor cells that bind octreotide. 25 Also, the in situ presence of SSTR2 mRNA in 
Clinical responders (with an increased score of global health exceeding 10 units), unchanged (less then 10 units difference from baseline) and nonresponders (with a decreased score exceeding 10 units) according to mean differences from baseline in CgA levels, ALP levels, Hemoglobin levels (Hb) and weight during the study
Predicting octreotide therapy KM Kalkner et al malignant cells of human prostatic tissue has been demonstrated, 26 further supporting the concept of treatment with somatostatin analogs for patients with hormone-refractory prostate cancer.
Clinical outcome
The present study demonstrated that four of 20 patients improved their health-related quality of life, in terms of global health score increasing more than 10 units in EORTC QLQ C-30 self-assessed questionnaire. The improvement could not be explained by increased consumption of analgesics or initiation of corticosteroids in this group of responders. The four patients with increased global health score, had a lower rate of PSA progression compared to the other patients, indicating that the Sandostatin treatment had a positive influence on the disease.
Previous reports have demonstrated conflicting results regarding treatment outcome using somatostatin analogs [8] [9] [10] [11] (summarized in Table 4 ). The majority reports positive effects, but one study has concluded that octreotide might even stimulate prostatic tumor growth but may also sensitize tumor cells to subsequent chemotherapy. 10 This is in contrast with the results of the present study and a pilot study, 9 using Octreotide acetate and in other trials using Lanreotid. 8, 11 It is difficult to compare results from studies with a small number of patients and the outcome is always influenced by selection. In the present report, an average of the global health score of patients at entry of the study was 53 and the 1-year overall survival was 57%, which illustrates that the patients at inclusion were highly affected by their disease. This result can be compared to the outcome reported by Figg et al. 8 where the 1-year global survival rate was 72%.
The toxicity is generally reported as tolerable. Toxicities included mild diarrhea, nausea and flatulence. The gastrointestinal side effects were self-limiting and occurred during the initial treatment cycles. The low grade of toxicity in the present trial is in agreement with other reports, although the patients were treated with a different somatostatin analog.
11,8
Prediction of treatment outcome
Since the majority of patients with hormone-refractory prostate cancer appear not to benefit from somatostatin analog treatment, the challenge is to identify the responders. In a small pilot study including patients with hormone-refractory prostate cancer the two responders had the strongest uptake on Octreotide scintigraphy. 9 This pattern was not confirmed in the present trial where abnormal skeletal uptake was seen in all but three patients, and where generally there were small differences in the grade of uptake. The high rate of patients with abnormal uptake compared to previous studies is possibly because often equivocal, possibly nonsignificant uptakes were seen on the whole-body scan. These findings were investigated using a tomographic (SPECT) protocol that is more sensitive in the detection of small lesions and lesions with small differences in contrast compared to normal tissue. 27 Our data even suggest that Predicting octreotide therapy KM Kalkner et al skeletal metastases, at least in hormone-refractory prostate cancer, to a certain degree routinely express somatostatin receptors. In this report, pretreatment levels of the neuroendocrine marker CgA failed to predict clinical responders. It has been suggested that CgA can be a valuable marker for the degree of neuroendocrine differentiation. 28 Recently, Berruti et al. 29 reported that CgA did not decrease during chemotherapy although frequently elevated in the hormone-refractory state of the disease and as a marker for poor prognosis. Interestingly, in our report the majority of treated patients had a decrease of CgA levels, indicating that Octreotide acetate therapy affects the hormone-refractory prostate cancer cells, but not in terms of improved health-related quality of life and PSA response.
With a small sample size is difficulty to demonstrate statistically significant differences and one can criticize this material in some aspects as being inhomogeneous with a wide range in PSA, different number of bone metastases and no information of tumor stage at diagnose. However, the inclusion of patients with PSA progression AND clinical symptoms or progression at bone scan, identify a hormone-refractory disease similar to the pre-PSA era. In that aspect it is a homogeneous group with a historical well-known overall survival close to 12 months. Finally, a clinically useful predictive method should be robust and provide information in a group of patients commonly presented for a physician.
Future studies on the presence of SSTR subtypes in hormone-refractory prostate cancers and tumor response to a set of specific SSTR agonists, may predict treatment outcome.
Conclusions
A minority of patients with hormone-refractory prostate cancer seems to benefit from somatostatin analog treatment with pain relief and improved health-related quality of life. The decrease and normalization of CgA levels in five patients during therapy indicates therapeutic activity but baseline Octreotide scintigraphy and baseline CgA could not identify clinical responders on Octreotide acetate therapy.
